Smalling Ralph, Foote MaryAnn, Molineux Graham, Swanson Steven J, Elliott Steve
Amgen Inc, One Amgen Center Drive, M/S 24-1-C, Thousand Oaks, CA 91320-1799, USA.
Biotechnol Annu Rev. 2004;10:237-50. doi: 10.1016/S1387-2656(04)10008-2.
Anti-erythropoietin (EPO)-induced pure red cell aplasia (PRCA) is an uncommon, potentially life-threatening condition in which the bone marrow stops manufacturing red blood cells. In the past few years, reports of drug-induced, anti-EPO antibody-mediated PRCA have increased substantially, with most cases attributed to the use of one erythropoiesis-stimulating protein, Eprex. A literature review was undertaken to document the reports of drug-induced PRCA, with all drugs and drug regimens. The sudden increase in reports of antibody-mediated PRCA is discussed.
抗促红细胞生成素(EPO)诱导的纯红细胞再生障碍性贫血(PRCA)是一种罕见的、可能危及生命的疾病,其骨髓停止制造红细胞。在过去几年中,药物诱导的、抗EPO抗体介导的PRCA报告大幅增加,大多数病例归因于使用一种促红细胞生成刺激蛋白——依普定。进行了一项文献综述,记录所有药物和药物治疗方案引起的药物性PRCA报告。讨论了抗体介导的PRCA报告的突然增加。